Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor, ALLKA Research and Zach Hartman for their picks. BioCGT Investor: Cardiff Oncology ...

Stocks of cancer treatment developers will be moving into the spotlight later this week when the annual meeting of the ...

Kura Oncology and Kyowa Kirin have shared details of the phase 2 win for their oral leukemia treatment ziftomenib as the FDA ...

Introduction Oncology drugs are medications used to prevent or treat cancer. These include chemotherapy, targeted therapy, immunotherapy, and h ...

Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...

Companies remain exposed to heightened risks between the world’s largest markets and are cautious of the stability of ...

SpringWorks Therapeutics, a U.S.-based clinical-stage biopharmaceutical company, has been acquired by German pharmaceutical ...

Accordingly, investing in AI-driven precision oncology companies presents a compelling long-term opportunity for investors. BioXcel: The company expedites the discovery and development of new ...